Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. nanosil4cancer

NanoSil4Cancer

Smart Multifunctional silica-based Nanoparticles for Targeted Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 NanoSil4Cancer project word cloud

Explore the words cloud of the NanoSil4Cancer project. It provides you a very rough idea of what is the project "NanoSil4Cancer" about.

vehicles    nanosil4cancer    sectorial    mesoporous    pct    interests    prototypes    communication    cells    cancer    feasibility    lowering    medical    individuate    environmental    nanoparticles    chemotherapy    sme    dosage    folic    silica    formulated    folate    patients    report    nevertheless    limited    stakeholder    strategical    customer    accelerate    commercial    depends    ep06745236    nanotechnologies    competence    internalized    optimized    efficacy    sensitive    market    attractiveness    drugs    nano    buy    90    receptor    prototype    device    bortezomib    molecules    business    marketing    technologies    overexpressing    release    pro    search    pharma    saving    minimize    antitumor    dramatically    active    agents    epo    patent    missing    thomson    healthcare    final    smart    sparing    platform    intracellular    acid    released    adherence    trend    drug    ph    minimizing    proprietary    big    therapeutic    normal    compartments    290b    acquire    fr    innovative    therapy    toxicity    13511    customers   

Project "NanoSil4Cancer" data sheet

The following table provides information about the project.

Coordinator		 NANOSILICAL DEVICES SRL 

Organization address
address: VIA PIETRO BUCCI CUBO 44A
city: RENDE
postcode: 87036
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Project website http://www.nanosilicaldevices.com/it/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2017-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NANOSILICAL DEVICES SRL IT (RENDE) coordinator 50˙000.00

Map

 Project objective

NanoSil4Cancer project will be able to accelerate the uptake of nanotechnologies, by developing, mesoporous silica-based prototypes of nano-vehicles, according to an innovative and proprietary approach (EP06745236), active in smart chemotherapy. This is aimed to minimize toxicity and the side effects of the traditional antitumor agents and to increase their therapeutic potential. This technology platform enables customers’ molecules to be formulated as pH–sensitive pro-drugs and introduced in smart nanoparticles able to reach the intracellular compartments of cancer cells where the drug is released. Development of new prototypes will lead to new patent applications. Recently we have developed and optimized a device, provided with folic acid, able to manage bortezomib release in cancer cells overexpressing folate receptor, FR (PCT-13511). The nanoparticles are only recognized and internalized by FR overexpressing cancer cells, where they release the drug, sparing normal cells. Nevertheless, our technology is general, not limited to a specific prototype, but depends on customer's needs, market and final users' needs. The feasibility study will individuate strategical market interests to address the prototypes production as business opportunities for our SME. Market trend and the role of Big Pharma will be defined to identify commercial partners and stakeholder to be involved in the project. We will buy sectorial report, we will use patent search such as EPO and Thomson, we will acquire missing competence in marketing and communication. The approach will represent a strong step forward in chemotherapy, improving the efficacy, lowering drug dosage (thus minimizing side effects for cancer patients and environmental impact), other than dramatically lowering EU Healthcare costs (up to 80-90% saving on non-adherence to the therapy costs, estimated in $290B/year), allowing Europe to increase its attractiveness in the field of innovative medical technologies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOSIL4CANCER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOSIL4CANCER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More